Home Cart Sign in  
Chemical Structure| 882-09-7 Chemical Structure| 882-09-7

Structure of Clofibric acid
CAS No.: 882-09-7

Chemical Structure| 882-09-7

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

Clofibric acid is an agonist of PPARα and can act as a hypolipidemic agent.

Synonyms: Chlorofibrinic acid; NSC 1149; CCRIS9254 Chlorfibrinic acid

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

DE Stock

US Stock

Asia Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of Clofibric acid

CAS No. :882-09-7
Formula : C10H11ClO3
M.W : 214.65
SMILES Code : CC(C)(OC1=CC=C(Cl)C=C1)C(O)=O
Synonyms :
Chlorofibrinic acid; NSC 1149; CCRIS9254 Chlorfibrinic acid
MDL No. :MFCD00004192
InChI Key :TXCGAZHTZHNUAI-UHFFFAOYSA-N
Pubchem ID :2797

Safety of Clofibric acid

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302
Precautionary Statements:P280-P305+P351+P338

Isoform Comparison

Biological Activity

Description
Clofibric acid (Chlorofibrinic acid), the active metabolite derived from lipid regulators such as Clofibrate, Etofibrate, and Etofyllinclofibrate, acts as a PPARα agonist and is known for its hypolipidemic effects. Additionally, Clofibric acid is used as an herbicide[1].[2].[3].

Clinical Trial:

NCT Number Conditions Phases Recruitment Completion Date Locations
NCT00144937 Peripheral Arterial Disease ... More >> Hypercholesterolemia Hypertension Diabetes Mellitus Smoking Less << Phase 4 Unknown - Spain ... More >> Hospital de Sabadell Sabadell, Barcelona, Spain, 08208 Less <<
NCT03031821 Prostate Cancer ... More >> Metabolic Syndrome Less << Phase 3 Not yet recruiting June 1, 2023 Canada, British Columbia ... More >> BC Cancer Agency - Vancouver Cancer Centre Not yet recruiting Vancouver, British Columbia, Canada, V5Z 4E6 Contact: Bernie Eigl, MD    604-877-6000    bernie.eigl@bccancer.bc.ca    Principal Investigator: Bernie Eigl, MD Less <<
NCT01047501 Hypertriglyceridemia Phase 3 Completed - -
NCT01047683 Hypertriglyceridemia Phase 3 Completed - -
NCT03058913 - Recruiting December 2025 United States, Illinois ... More >> Outpatient Endovascular Interventional Society (OEIS) Recruiting Hoffman Estates, Illinois, United States, 60169 Contact: Jeff Carr    903-521-6004    jeffcarr@me.com Less <<
NCT01529424 Hypertriglyceridemia Phase 2 Completed - United States, North Carolina ... More >> Farmville Internal Medicine Farmville, North Carolina, United States, 27828 Mark R. Cervi Greenville, North Carolina, United States, 27834 Physicians East, Quadrangle Medical Specialists Greenville, North Carolina, United States, 27834 Carolina East Family Medicine Greenville, North Carolina, United States, 27858 Eastern Carolina Physicians Kinston, North Carolina, United States, 28504 Natalie A Doyle, MD PA Wilson, North Carolina, United States, 27893 Canada, Quebec Isis Investigational site Chicoutimi, Quebec, Canada Less <<
NCT01492361 Cardiovascular Diseases Phase 3 Completed - -
NCT02282423 Diabetes Obes... More >>ity Less << Not Applicable Terminated(PI job change) - United States, Arizona ... More >> Mayo Clinic Scottsdale, Arizona, United States, 85259 Less <<
NCT00309712 Type II Diabetes Mellitus ... More >> Mixed Dyslipidemia Less << Not Applicable Completed - United States, Utah ... More >> McKay Dee Hospital Ogden, Utah, United States, 84403 LDS Hospital Salt Lake City, Utah, United States, 84143 Less <<
NCT01022450 - Unknown - Taiwan ... More >> National Taiwan University Hospital Recruiting Taipei, Taiwan, 10051 Contact: Kwan-Dun Wu, MD, PhD    886-2-23123456 ext 65014    kdwu@ntuh.gov.tw    Principal Investigator: Fe-Lin L Wu, MSCP, PhD          Sub-Investigator: Kwan-Dun Wu, MD, PhD Less <<
NCT02886299 Fenofibrate/Simvastatin Compar... More >>ison Less << Phase 4 Completed - -
NCT03430284 Diabetes Mellitus, Type 2 Phase 4 Recruiting December 31, 2020 China, Shandong ... More >> Shandong Provincial Hospital Not yet recruiting Jinan, Shandong, China, 250021 Contact: Shanshan Shao    +8653168776094    shaoshanshan11@126.com    Shandong Provincial Hospital Recruiting Jinan, Shandong, China Less <<
NCT00542178 Diabetic Retinopathy Phase 3 Completed - United States, Minnesota ... More >> The Berman Center for Clinical Research Minneapolis, Minnesota, United States, 55404 United States, New York Columbia University New York, New York, United States, 10032 United States, North Carolina Wake Forest University Health Sciences Winston-Salem, North Carolina, United States, 27157 United States, Ohio Case Western Reserve University Cleveland, Ohio, United States, 44106-4951 United States, Tennessee Veterans Affairs Memphis, Tennessee, United States, 38104-2193 United States, Washington University of Washington Seattle, Washington, United States, 98109 Canada, Ontario McMaster University Hamilton, Ontario, Canada, L8L 2X2 Less <<
NCT00535925 Diabetic Nephropathy Phase 4 Unknown September 2012 Italy ... More >> Department of Clinical and Experimental Medicine, Second University of Naples Naples, Italy, I-80131 Less <<
NCT00542178 - Completed - -
NCT02965911 Primary Biliary Cirrhosis Phase 1 Phase 2 Recruiting January 2019 China ... More >> Beijing 302 hospital Recruiting Beijing, China, 100039 Contact: Zhengsheng Zou, Dr.          Principal Investigator: Zhengsheng Zou, Dr. Less <<
NCT03323788 - Recruiting August 1, 2018 United States, Arizona ... More >> The University of Arizona Recruiting Tucson, Arizona, United States, 85724 Contact: Oscar Parra, MADM    520-626-6485    oscardp@email.arizona.edu    Principal Investigator: Lawrence Mandarino, PhD Less <<
NCT03649269 Hypertriglyceridemia Not Applicable Completed - -
NCT02863185 Chronic Kidney Disease Phase 4 Recruiting December 2019 Korea, Republic of ... More >> Won Suk An Recruiting Busan, Korea, Republic of, 602-715 Contact: Won Suk An, M.D., Ph.D.    +82-51-240-2811    anws@dau.ac.kr    Dong-A University Not yet recruiting Busan, Korea, Republic of, 602715 Contact: Su Mi Lee, MD    +822405549    promise131@hanmail.net Less <<
NCT00451464 - Completed - Taiwan ... More >> Pan-Chyr Yang Taipei, Taiwan, 100 Less <<
NCT03449784 - Recruiting May 1, 2041 France ... More >> Uhmontpellier Recruiting Montpellier, France, 34295 Contact: cyril BREUKER       c-breuker@chu-montpellier.fr Less <<
NCT01515241 Heterozygous Familial Hypercho... More >>lesterolemia Less << Phase 2 Completed - Canada, Quebec ... More >> Montreal Heart Institute Montreal, Quebec, Canada, H1T1C8 Less <<
NCT00116636 HIV Infections Phase 2 Completed - United States, Texas ... More >> Therapeutic Concepts, P.A. Houston, Texas, United States, 77004 Less <<
NCT03345901 Diabetic Retinopathy ... More >> Diabetic Macular Edema Less << Phase 3 Recruiting January 2023 -
NCT00934219 Hypertriglyceridemia Phase 4 Unknown December 2012 United States, Ohio ... More >> Jewish Hospital Cholesterol Center Recruiting Cincinnati, Ohio, United States, 45229 Less <<
NCT00362934 Hyperlipidemia Phase 3 Completed - -
NCT00349375 Hyperlipidemia Phase 3 Completed - -
NCT02548832 Mixed Dyslipidemia Phase 2 Unknown July 2016 Mexico ... More >> Institute of Experimental and Clinical Therapeutics (INTEC), CUCS, University of Guadalajara Recruiting Guadalajara, Jalisco, Mexico, 44340 Contact: Esperanza Martínez Abundis, PhD Science    (33) 1058-5200 ext 34211    esperanzamartnezabundi@yahoo.com Less <<
NCT01101503 Endothelial Dysfunction Phase 2 Recruiting December 2020 China, Hubei ... More >> Department of Endocrinology Recruiting Wuhan City, Hubei, China, 430070 Contact: Xiang Guangda, MD, Ph D    +862768878410    Guangda64@hotmail.com    Principal Investigator: Xiang Guangda, MD, Ph D Less <<
NCT00362206 Hyperlipidemia Phase 3 Completed - -
NCT01462877 - Completed - -
NCT01025492 Dyslipidemia Phase 4 Terminated(Collaborator/corpor... More >>ate sponsor withdrew funding and permission to continue.) Less << - United States, Utah ... More >> University of Utah Salt Lake City, Utah, United States, 84108 Less <<
NCT00352183 Cardiovascular Diseases Phase 3 Completed - -
NCT01148004 HIV Fenofibra... More >>te Protease Inhibitors Hypertriglyceridemia Glucuronosyltransferase Less << Phase 1 Completed - United States, Maryland ... More >> National Institutes of Health Clinical Center, 9000 Rockville Pike Bethesda, Maryland, United States, 20892 Less <<
NCT00037401 - Completed - -
NCT01462877 Dyslipidemias ... More >> Cardiovascular Diseases Hypertriglyceridemia Less << Phase 4 Completed - China ... More >> Site Reference ID/Investigator# 64695 Xiamen, China, 36100 Less <<
NCT01477944 - Completed - -
NCT01602913 - Completed - -
NCT01674712 Dyslipidemia Phase 3 Completed - -
NCT00965315 - - - -
NCT01385020 Healthy Subjects Phase 4 Completed - Taiwan ... More >> National Taiwan University Hospital Taipei, Taiwan Less <<
NCT01674712 - Completed - -
NCT01654731 PBC Phase 3 Completed - France ... More >> Hepatology department - Hopital Saint Antoine Paris, France, 75012 Less <<
NCT00728910 Dyslipidemia Phase 2 Completed - United States, Pennsylvania ... More >> CTRC (Clinical Translational Research Center) Philadelphia, Pennsylvania, United States, 19104 Less <<
NCT00728910 - Completed - -
NCT03110432 - Recruiting February 16, 2021 Germany ... More >> Medizinische Klinik und Poliklinik III Recruiting Dresden, Germany Contact: Andreas Birkenfeld, MD Less <<
NCT00458055 Coronary Arteriosclerosis ... More >> Hypoalphalipoproteinemias Genetic Diseases, Inborn Less << Not Applicable Completed - Canada, Quebec ... More >> MUHC-Royal Victoria Hospital Montreal, Quebec, Canada, H3A 1A1 Less <<
NCT00156169 Low HDL Cholesterol Phase 3 Completed - -
NCT02530827 - Completed - -
NCT00491400 Diabetes Mellitus ... More >> Metabolic Syndrome Less << Not Applicable Terminated(Insufficient enroll... More >>ment) Less << - United States, Massachusetts ... More >> Boston Medical Center Boston, Massachusetts, United States, 02118 Less <<
NCT00243672 Atherosclerosis Phase 4 Withdrawn(The study chair chan... More >>ged his employment, the realization of the study was not possible) Less << - -
NCT01025492 - Terminated(Collaborator/corpor... More >>ate sponsor withdrew funding and permission to continue.) Less << - -
NCT03586674 Chronic Cholestasis Phase 2 Completed - Egypt ... More >> Dr. Yassin Abdel Ghaffar Charity Center For Liver Diseases & Researches Cairo, Nasr City, Egypt National liver istitute Shibīn Al Kawm, Egypt Less <<
NCT01527318 Neutral Lipid Storage Disease Phase 4 Completed - Netherlands ... More >> Maastricht University Medical Center Maastricht, Limburg, Netherlands, 6200MD Less <<
NCT00491400 - Terminated(Insufficient enroll... More >>ment) Less << - -

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

4.66mL

0.93mL

0.47mL

23.29mL

4.66mL

2.33mL

46.59mL

9.32mL

4.66mL

Dissolving Methods
Please choose the appropriate dissolution scheme according to your animal administration guide.For the following dissolution schemes, clear stock solution should be prepared according to in vitro experiments, and then cosolvent should be added in turn:

in order to ensure the reliability of the experimental results, the clarified stock solution can be properly preserved according to the storage conditions; The working fluid for in vivo experiment is recommended to be prepared now and used on the same day;

The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound.
Protocol 1
Protocol 2

References

 

Historical Records

Categories